Relmada Therapeutics Inc

(OTC:RLMDD)

Symbol has changed to a new ticker symbol

(RLMD)

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of proven drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The product portfolio of the company includes d-Methadone, an N-methyl-D-aspartate receptor antagonist for treating depression and neuropathic pain; LevoCap ER, an abuse-resistant, the dosage form of the opioid analgesic levorphanol; BuTab an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Its lead product d-Methadone is an oral agent for the treatment of depression, pain, and other potential conditions affecting the brain functions.

Contact Information

Website: www.relmada.com
Email: info@relmada.com
Main Phone: +1 646 876-3459
Address: 880 Third Avenue
Address 2: 12th Floor
State: NY
City / Town: New York
Country: USA
Postal Code: 10022

Issuer Information

Exchange: OTCQB
CEO: Sergio Traversa
Employees: 4
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A